Kornimate/medical-research-clean huggingface dataset:
microbiota and immunoassay in women with and without endometriosis: a pilot study

Conditions: Endometriosis; Endometriosis-related Pain

Summary: endometriosis is an estrogen-dependent chronic inflammatory disease characterized by the presence of endometrial tissue outside the uterine cavity. this pathology has a prevalence of about 5-10% in reproductive-aged women. endometriosis therapy uses two options: surgical or medical (hormonal) but none can be considered completely resolving. related signs and symptoms include dysmenorrhea, dyspareunia, infertility, dysuria and dyschezia. in addition to typical gynecological symptoms, gastrointestinal symptoms (bloating, nausea, constipation, diarrhea and vomiting) affect up to 90% of patients with endometriosis. despite its high prevalence and associated morbidity, its etiology is still unclear and is thought to be multifactorial, and genetic, hormonal, environmental and immunological factors contribute to it. several studies have shown a significant association between abnormal immune response and maintenance of disease activity in women with endometriosis. the microbiome contains all the genetic material of microbes, including bacteria, fungi, viruses and archaea, which live inside the host and regulate various physiological functions. the set of these bacteria, fungi, viruses and archaea is called a microbiota. the influence of the microbiome on immunomodulation and the development of various inflammatory diseases is well established. conversely, little is known about the presence and composition of the microbiome in the female reproductive system and its role in the development of endometriosis or other gynecological conditions. considering the altered inflammatory state typical of endometriosis, it seems logical to postulate a potential role of the microbiome in the etiopathogenesis of this pathology. interestingly, the microbiome affects estrogen metabolism and estrogen affects the gut microbiome. since endometriosis is an estrogen-dependent disease, a picture of intestinal dysbiosis resulting in abnormal circulating estrogen levels could potentially contribute to the development of this disease.


Eligibility criteria:
inclusion criteria: * bmi \<30 kg / m2 * no hormonal therapy (estrogen-progestin, progestogen, gnrh analogues) in progress for at least 1 month * the endometriosis group include women who will undergo surgery for endometriosis. the control group include women who will undergo surgery for other gynecological indications (i.e .: abdominal surgical emergencies, tubal infertility, non-endometriotic ovarian cysts) in which the presence of endometriosis will be excluded during the surgery. exclusion criteria: * hormonal therapy in progress (estrogen-progestins, progestins, gnrh analogues) * antibiotic and / or probiotic therapy in the 8 weeks before the samples * pregnancy * menopausal state * bmi ≥ 30 kg / m2 * presence of active systemic diseases, neoplasms, positive clinical history for autoimmune diseases, active vaginosis or positive history for pelvic inflammatory disease

Keywords: diagnosis microbiota immunoassay
human chorionic gonadotropin supplementation prior to in-vitro fertilization treatment in poor responders

Conditions: Infertility

Summary: in an era of delayed fertility plans, there is increasing need for fertility treatment in older women with poor response. human chorionic gonadotropin (hcg) supplementation prior to treatment, as a thecal stimulant, may improve folliculogenesis and ovarian response.


Eligibility criteria:
inclusion criteria: * women \>39 years on ivf treatment exclusion criteria: * polycystic ovary syndrome * any allergy to injection of human chorionic gonadotropin before

Keywords: in-vitro fertilization poor responders human chorionic gonadotropin fertility agents, female
isokinetic strengthening of hip muscles effect on pelvic floor muscles function in females with sui

Conditions: Isokinetic Strengthening; Pelvic Floor Muscles; Stress Urinary Incontinence (SUI)

Summary: this study will be conducted to investigate the impact of isokinetic strengthening of hip muscles on pelvic floor muscles function in women experiencing stress urinary incontinence does isokinetic strengthening of hip muscles impact pelvic floor muscles function in women experiencing stress urinary incontinence?


Eligibility criteria:
inclusion criteria: * patients diagnosed with stress urinary incontinence * age between 30 and 50 years exclusion criteria: * low back pain * lower limb muscle pathology and/or joint degeneration * cardiovascular, metabolic or pulmonary disease * body mass index (bmi) \> 30 kg/m2.
romosozumab effects on bone density, muscle mass, and spine surgery outcomes

Conditions: Osteoporosis, Post-menopausal

Summary: the goal of this clinical trial is to learn if romosozumab (evenity) can improve bone and muscle health in postmenopausal women with osteoporosis who are undergoing lumbar spine surgery. the main questions it aims to answer are: * does romosozumab improve bone strength and reduce the risk of complications during and after spine surgery? * does romosozumab increase muscle mass and help patients recover better from surgery? researchers will compare romosozumab (a monthly injection) to alendronate (a weekly pill), both approved treatments for osteoporosis, to see which is more effective in this surgical setting. participants will: * be randomly assigned to receive romosozumab or alendronate * take standard vitamin supplements and receive a one-time dose of zoledronic acid near the end of the study * attend five study visits over about 12 months * undergo bone scans, muscle imaging, and complete health questionnaires before and after surgery


Eligibility criteria:
inclusion criteria: * post-menopausal female * diagnosed with osteoporosis (t-score ≤ -2.5). * scheduled for or planning posterior lumbar fusion for degenerative disease, at least 3 months in the future. * able to provide informed consent. exclusion criteria: * history of prior spinal surgery. * male sex. * current or prior use of osteoporosis medications within the past 3 years. * current use of anabolic agents other than romosozumab. * current use of androgen receptor (ar) modulators, such as testosterone replacement therapy or selective androgen receptor modulators (sarms). * severe renal impairment (egfr \< 30 ml/min/1.73m²). * known hypersensitivity to romosozumab, alendronate or zoledronic acid. * severe spinal deformity. * active malignancy or history of malignancy within the past 5 years. * any secondary cause of decreased bmd (e.g., hyperparathyroidism). * stroke or myocardial infarction in the past year. * planned fusion involving more than 4 levels. * uncorrected hypocalcemia and/or hypovitaminosis d * esophageal abnormalities
mechanisms of impaired hiv-associated b cell and pneumococcal vaccine responses

Conditions: HIV; Pneumococcal Infections; Pneumococcal Vaccines

Summary: human immunodeficiency virus (hiv) infection is complicated by high rates of infections and cancers which are often the cause of death rather than the hiv/acquired immune deficiency syndrome (aids) virus itself. treatment of hiv with antiretroviral medications has decreased the frequency of many complications by over 90%, but bacterial pneumonia remains extremely high. current vaccines are not very effective in preventing these infections in patients with hiv infection. the investigators are studying the cells (b cells) that make antibodies to fight infection by binding to and killing bacteria. the goal is to understand how hiv impairs the ability of b cells to make antibodies in sufficient quantity and of sufficient quality to protect patients with hiv to learn how to enhance protection against these infections. the investigators also seek to understand the role of the bacteria (specifically streptococcus pneumoniae) that normally live in the nose and throat in the development of pneumonia and other infections.


Eligibility criteria:
inclusion criteria: for hiv-infected subjects: * adults aged 18-55 years * \>200 cd4+ t-cells/microliter * no antiretroviral therapy (at the time of nasal swab/week 0) * receiving antiretroviral therapy for \>6 weeks (at the time of vaccination/week 12) for hiv-seronegative controls: * adults aged 18-55 years exclusion criteria: for all subjects: * age \ 55 years * history of prior pneumococcal vaccination * immunosuppressive therapy, defined as: prednisone \>15mg/day currently or \>14 days in the past 3 months, cytotoxic agents, anti-metabolites, cyclosporine, anti-tumor necrosis factor, b cell monoclonal antibodies * current or chronic pulmonary infection (bacterial, fungal, mycobacterial), pneumonia, or rhinosinusitis within 2 months * chronic lung disease * renal insufficiency, defined as serum creatinine \>1.6 * active liver disease, including hepatitis c virus infection * history of splenectomy * history of antibacterial therapy within 3 months of nasal swab (week 0) * current alcohol abuse * chronic heart disease * diabetes * current cigarette smoking

Keywords: hiv streptococcus pneumoniae infection streptococcus pneumoniae colonization pneumococcal vaccines prevnar pneumovax nasopharyngeal microbiome
cryotherapy of sclerotomy sites for prevention of late postvitrectomy diabetic hemorrhage

Conditions: Late Postvitrectomy Diabetic Hemorrhage.

Summary: late vitreous hemorrhage in postvitrectomized diabetic eyes may be due to fibrovascular tuft formation in sclerotomy sites. cryotherapy of sclerotomy sites may prevent bleeding by regressing the fibrovascular tuft. this study will detect the safety and efficacy of cryotherapy of sclerotomy sites for prevention of late vitreous hemorrhage in vitrectomized diabetic eyes.


Eligibility criteria:
inclusion criteria: * diabetic retinopathy cases undergoing vitrectomy exclusion criteria: * history of deep vitrectomy or cataract surgery * renal failure * silicone oil injection during surgery * early rebleeding * history of antithrombotic drugs usage

Keywords: rebleeding diabetic vitreous hemorrhage cryotherapy
comparison between ultrasound-guided genicular nerve phenol neurolysis and intra-articular steroid injections

Conditions: Osteoarthritis, Knee; Chronic Knee Pain

Summary: genicular nerve neurolysis (gn) constitutes a relatively novel technique, whereby different chemical compounds (i.e. alcohol, phenol) are injected in close proximity to the genicular nerves of the knee joint, with the intention to exert a neurolytic effect by denaturing proteins resulting in wallerian degeneration distal to the lesion. based on the preliminary evidence and considering the potential benefits of the technique, we hypothesized that ultrasound-guided genicular chemical neurolysis with phenol is superior in terms of pain relief at 3 months, when compared to intra-articular steroid (ias) injection.

this study will allow us to determine if ultrasound-guided phenol genicular neurolys is superior to intra-articular steroid injection in terms of analgesia and functional outcomes, providing a more effective and long-lasting alternative for patients with chronic knee pain secondary to osteoarthritis

Eligibility criteria:
inclusion criteria: * severe knee pain for more than 6 months, defined as numeric rating scale (nrs) score of 6 and greater, unresponsive to conservative medical treatment * radiological oa grade 2 to 4 (kellgren-lawrence scale) exclusion criteria: * previous total knee replacement on the index knee * prior knee radiofrequency ablation on the index knee * connective tissue diseases with knee involvement (e.g. rheumatoid arthritis) * body mass index ≥ 40 kg/m2 * uncontrolled coagulopathy, defined as supratherapeutic dose of anticoagulation medication * allergy to local anesthetics * unstable opioid consumption, defined as an increase \>10% in dosage during the last 3 months prior to recruitment.

Keywords: phenol injections, intra-articular steroids nerve block
the effect of platelet-rich plasma-fibrin glue in combination with vitamin e and c for treatment of non-healing diabetic foot ulcers

Conditions: Diabetic Foot Ulcers; Diabetic Wound

Summary: the aim of this study is to evaluates the chance of non-healing diabetic foot ulcers repair by reducing oxidative stress caused by diabetes by taking vitamin e and c supplements along with the use of platelet-rich plasma-fibrin glue as an effective treatment for wound healing.


Eligibility criteria:
inclusion criteria: 1. dfu is classified as wagner 1 -2 on the wagner classification system. 2. persons with type 1 or type 2 diabetes with a non-healing ulcer of at least 4 weeks duration. 3. if more than one non-healing wound is present, the largest of the wounds that is classified as a wagner 1- 2. 4. the index ulcer had to be clinically non-infected. 5. ankle brachial index (abi) greater than or equal to 0.7. 6. hemoglobina1c (hba1c) \< 12 7. index foot ulcer located on the plantar, medial, or lateral aspect of the foot (including all toe surfaces). 8. wound area (length x width) measurement between 2 cm2 and 20 cm2. 9. non-use of drugs that may interfere with wound healing, such as corticosteroids, immunosuppressive agents, and cytotoxic agents. 10. no smoking, alcohol or drug addiction. 11. approved, informed, signed consent. exclusion criteria: 1. previous consumption of vitamin e and c supplements. 2. index ulcer has exposed tendons, ligaments, muscle, or bone. 3. confirmed presence of osteomyelitis, or if osteomyelitis is suspected. 4. patients with renal deficiency, hepatic failure, has known immune insufficiency and cancer. 5. subject is pregnant or plans to become pregnant during the duration of the trial. 6. patient's blood vessels are non-compressible for abi testing. 7. patient is known to have a psychological, developmental, physical, emotional disorders. 8. received systemic corticosteroids or immunosuppressive agents.

Keywords: platelet-rich plasma-fibrin glue dfu vitamin e vitamin c non-healing diabetic foot ulcers
catheter-directed sclerotherapy versus surgical resecction: randomized controlled trial comparing ovarian function and therapeutic efficacy after treatment of ovarian endometrioma

Conditions: Ovarian Endometrioma

Summary: the primary purpose of this study is to compare residual ovarian function and therapeutic efficacy of surgical resection and catheter-directed sclerotherapy for ovarian endometrioma

screening * history, physical examination * vital signs * laboratory test (serum amh, ca-125, he-4) / ekg / mri * ehp-30 intervention * surgical enucleation or catheter-directed sclerotherapy * laboratory test / ekg * adverse event monitoring follow-up visit #1 (1 month) * vital signs * lab test (amh, ca-125) / ultrasound * adverse event monitoring follow-up visit #2 (6 months) * vital signs * lab test (amh, ca-125) / ultrasound / contrast-enhanced mri * ehp-30 follow-up visit #3 (12months) * vital signs * lab test (amh, ca-125) / ultrasound * ehp-30

Eligibility criteria:
inclusion criteria: 1. women with symptomatic fibroids (age: 20 - 60 years old) exclusion criteria: 1. gynecologic malignancy 2. ongoing infection or inflammation 3. coagulopathy (platelet \ 1.5) 4. extraovarian endometriosis 5. serum amh of 5 or higher 6. drug allergy 7. illiteracy 8. pregnancy

Keywords: endometrioma resection enucleation sclerotherapy ovarian function
automatic real-time diagnosis of gastric mucosal disease using pcle with artificial intelligence

Conditions: Gastric Diseases; Artificial Intelligence; Confocal Laser Endomicroscopy

Summary: probe-based confocal laser endomicroscopy (pcle) is an endoscopic technique that enables real-time histological evaluation of gastric mucosal disease during ongoing endoscopy examination. however this requires much experience, which limits the application of pcle. the investigators designed a computer-aided diagnosis program using deep neural network to make diagnosis automatically in pcle examination and contrast its performance with endoscopists.


Eligibility criteria:
inclusion criteria: * aged between 18 and 80; * agree to give written informed consent. exclusion criteria: * patients under conditions unsuitable for performing cle including coagulopathy , impaired renal or hepatic function, pregnancy or breastfeeding, and known allergy to fluorescein sodium; * inability to provide informed consent
safety and efficacy of the toothwave power toothbrush for extrinsic stain reduction

Conditions: Tooth Discoloration

Summary: this study is a single blind, prospective study aimed to evaluate the safety and efficacy of the silk'n toothwave power toothbrush for stains reduction and improvement of teeth shade.

the study includes 84 treatment sessions, twice a day, and 4 clinic visits over a period of 6 weeks. one treatment group (silk'n power toothbrush - toothwave) and 1 control group (an ada approved power toothbrush (ptb)) will participate in the study. for each patient, efficacy assessment data will be collected at baseline, 4 weeks, and at 6 weeks. the average stain data will be calculated for each group. treatment is defined as a timed, 2 minute brushing of the teeth according to the manufactur-er's instructions, twice daily (morning and evening). brushing will be undertaken using the silk'n toothbrush and standard fluoride toothpaste. the control group will use an ada ac-cepted ptb and the same standard fluoride toothpaste.

Eligibility criteria:
inclusion criteria: 1. adult subjects aged 18-70, that are in good health. 2. subjects should have notable extrinsic dental stains on the front teeth with a total extrin-sic facial tooth stain score ≥14 according to the lsi. 3. the subjects should understand the information provided about the investigative nature of the treatment, possible benefits and side effects. subjects will sign the informed consent form. 4. the subjects should be willing to comply with the study procedure and schedule, includ-ing the follow up visits, and will refrain from using any other teeth whitening technologies during this period. 5. the subject did not perform any procedure for teeth whitening (either at home or in clin-ic) at least 3 years prior to participating in the study exclusion criteria: 1. any condition that might make it unsafe for the subject to participate in the study, at the discretion of the investigator 2. pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body. 3. pregnant or nursing by subject report. 4. any active condition in the oral cavity at the discretion of the investigator. 5. any surgery in the treated area within 3 months prior to treatment, or before complete healing. 6. subjects that do not brush regularly. 7. regular tobacco smokers.
incidence of trauma induced coagulopathy in patients with prehospital administration of fibrinogen

Conditions: Trauma; Hemorrhage; Coagulopathy

Summary: the purpose of the study is to find out the incidence of trauma induced coagulopathy in patients with severe trauma who received fibrinogen prior admission to emergency department during prehospital care.

the study will commence following the approval by the ethics research committee. all patients admitted to emergency department during the study will be enrolled after fulfilling the inclusion criteria and in the absence of any exclusion criteria. informed consent will be requested. after admission to emergency department the blood samples will be taken and blood tests and viscoelastic tests will be performed. all data and results will be entered in the study form. statistical analysis will be performed and incidence of trauma induced coagulopathy estimated. in addition, 28-day mortality and the incidence of thromboembolic complications will be monitored.

Eligibility criteria:
inclusion criteria: * multiple trauma, injury severity score (iss) ≥16 * administration of fibrinogen in prehospital care * age 18-80 years exclusion criteria: * iss 75 * pregnancy * therapeutic anticoagulation * therapeutic antiaggregation

Keywords: trauma induced coagulopathy multiple trauma fibrinogen
the development, implementation and evaluation of clinical pathways for chronic obstructive pulmonary disease (copd) in saskatchewan

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: chronic obstructive pulmonary disease (copd) has substantial economic and human costs. to minimize these costs high quality guidelines have been developed. however, development of guidelines alone rarely results in changes to practice. one method of integrating guidelines into professional practice is the use of clinical pathways (cpws). the investigators are working with local stakeholders to develop cpws for copd with the aims of improving quality of care and guideline adherence while reducing healthcare utilization. the cpws will utilize several steps including: standardizing diagnostic training, implementing and unifying common components of chronic disease care, coordinating the provision of education and reconditioning programs, and ensuring disease specific care utilizes and delivers evidence-informed practices. in addition, the investigators have worked to identify evidence-informed strategies for the implementation of the cpws. efforts are underway to tailor these implementation strategies for the local context. the investigators will conduct a three-year quantitative health services research project using an interrupted time series (its) design in the form of a multiple baseline approach with control groups. the cpw will be implemented in two saskatchewan health regions (experimental groups) and two health regions will act as controls (control groups). the experimental and control groups will each contain one urban and one rural health region. this project is expected to improve quality of life and reduce healthcare utilization. the project will also provide evidence on the effects of cpws in both urban and rural settings. if the pathways are found effective the investigators will work with all stakeholders to implement similar cpws for the remaining health regions in the province.


Eligibility criteria:
inclusion criteria: * all individuals with diagnosed chronic obstructive pulmonary disease (copd) exclusion criteria: * n/a

Keywords: clinical pathway cpw chronic obstructive pulmonary disease copd protocol adherence readmission length of stay cost
blood collection of patient presenting in the ed and prescribed a bnp

Conditions: Heart Failure

Summary: plasma specimen collected from patients presenting in the emergency department (ed) with or without heart failure (hf) and prescribed a bnp.

plasma samples are collected from a minimum of 400 subjects. specimens are used to confirm the currently accepted bnp cut off as and aid in the diagnosis and assessment of hf. stored specimens for future use in bnp assay development.

Eligibility criteria:
inclusion criteria: * males and females \>21 years of age * able to understand and willing to provide informed consent * present in to ed * bnp test requested exclusion criteria: * males and females\< 21 years * unable to provide informed consent * not presenting to ed * hemolyzed sample

Keywords: ed bnp